Abstract
To assess the antibacterial activity of ceftobiprole against Methicillin-resistant
(MRSA) and
(
) from various body specimen types and different patterns of resistance.
A retrospective cohort study with a total of 49 MRSA and 99
isolated in the Microbiology Laboratory at King Saud University Medical City, Riyadh, Saudi Arabia, between 2018-2019, were used. Isolates were randomly selected from various specimen types. The minimum inhibition concentration (MIC) of ceftobiprole was determined by E-test. Breakpoints carried out by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were used to assess antibiotic susceptibility.
Approximately 100% of the MRSA isolates were susceptible with MIC50/90 value of 1/1.5 mg/L while 69.8% of multi-drug resistant (MDR)
isolates were resistant with MIC50/90 value of 16/32 mg/L.
The excellent activity of ceftobiprole against MRSA would have major implications in management of the patients with serious infections, as an empirical treatment or alternative to vancomycin. Ceftobiprole has a very low activity against MDR
, and its susceptibility should be tested prior to use for treatment.